Cabbacis Secures U.S. Patent for Innovative Vaporizer Pod Blends Aimed at Tobacco Harm Reduction

Download IPFS

Cabbacis Inc., a U.S.-based tobacco product manufacturer focused on harm-reduction alternatives, has been granted a new U.S. patent for its unique vaporizer pod technology that blends tobacco and hemp. The newly issued patent, U.S. Patent No. 12,349,724, underscores the company’s expanding intellectual property portfolio and supports its mission to offer smokers less harmful alternatives. The patent, valid through July 2038, reinforces Cabbacis’ commitment to innovation in a market where traditional smoking habits persist despite growing health concerns.

The patent covers vaporizer pods for oral electronic devices, also referred to as heat-not-burn products, which include a combination of reconstituted tobacco and hemp. The claims specifically focus on blends containing at least 5 mg of either conventional- or reduced-nicotine reconstituted tobacco with at least 5 mg of hemp. Reconstituted tobacco is commonly used in closed-end vapor systems such as IQOS®, Ploom®, and glo®. What sets Cabbacis apart is its emphasis on sensory satisfaction through hemp inclusion, delivering a unique taste experience not found in standard products.

Cabbacis, trading under the ticker OTCQB: CABI, already holds two additional patents in the U.S. for similar vaporizer technologies, patents 10,777,091 and 10,973,255, and maintains a global footprint of intellectual property protections across more than 30 countries, including major tobacco markets like China, Brazil, and Japan.

According to Chief Executive Officer Joseph Pandolfino, “This patent, when taken in tandem with our existing patents, comprehensively covers any ratio of reduced- or conventional-nicotine tobacco and hemp in vaporizer and cigarette products worldwide.” His remarks signal the company’s continued effort to secure leadership in the growing reduced-nicotine and alternative smoking sector.

Cabbacis’ flagship line, iBlend™, includes reduced-nicotine vaporizer pods and cigarettes both containing hemp. These products aim to help smokers reduce consumption or transition away from traditional cigarettes. The iBlend™ cigarettes contain around 95% less nicotine than standard brands. A recent clinical trial found these products both satisfying and effective at reducing cravings, as measured by the standardized modified Cigarette Evaluation Questionnaire (mCEQ).

In addition to developing hemp-tobacco hybrid products, Cabbacis plans to commercialize reduced-nicotine cigarettes and little cigars without hemp, further expanding their offerings to reach a broader demographic of adult smokers.

With seven U.S. patents and a total portfolio of 35 issued patents worldwide, Cabbacis is positioning itself as a leader in harm-reduction innovation. Its strategy is grounded in science and supported by growing public and clinical interest in alternatives to high-nicotine tobacco products.

As regulatory scrutiny on conventional tobacco continues to mount, companies like Cabbacis that focus on less harmful, science-backed alternatives may gain an edge, especially as consumer interest shifts toward products that help reduce or quit nicotine use altogether.